Federal government is responding to criticism of Pharma Germany - new duties for sustainability reporting are concerned

Federal government is responding to criticism of Pharma Germany - new duties for sustainability reporting are concerned

new draft laws on reporting on company sustainability

The Federal Government recently decided on a celebrated draft law to comply with the Corporate Sustainability Reporting Directive (CSRD) of the European Union. This decision is the result of many years of discussions and criticism, especially Pharma Germany, the largest association in the pharmaceutical industry in Germany. Pharmaceutical Germany has managed to move the government to its previous fears in connection with the interaction of the Lief chain law and the sustainability reporting.

The implemented changes mean that the double burden, which threatened by the supply chain folding law and the law on sustainability reporting, was postponed by December 31, 2025. This is undoubtedly good news for companies in Germany, since this saves them additional obligations.

Nevertheless, bureaucracy remains an important challenge for the pharmaceutical industry. The new requirements for sustainability reporting bring considerable effort and financial burdens for companies. Pharma Germany's general manager, Dorothee Brakmann, emphasized that further tightening of the bureaucracy by the EU Commission and the Federal Government had to be avoided. Otherwise, this could lead to a distraction of valuable resources of research and development activities in order to comply with increasing reporting obligations.

In particular, medium -sized companies that gradually fall under the duties for sustainability reporting from 2025 are heavily burdened. This is a particularly critical situation for the innovation -driven pharmaceutical industry.

Regardless of the challenges, Pharma Germany sees sustainability reporting as an opportunity to make the diverse services of the pharmaceutical industry transparent in this area. However, the reporting obligations must take place within a reasonable framework that receives and promotes the ability to act. The aim is to reconcile sustainability and competitiveness.

The decisions of the federal government and the satisfaction of Pharma Germany show that the topic of sustainability reporting is an important aspect for companies and society as a whole. The pharmaceutical industry, represented by Pharma Germany, makes a significant contribution to the supply of drugs in Germany. Almost 80 percent of the over -the -counter and almost two thirds of the prescription medicines, as well as a large part of the material medical devices, are manufactured by companies in Pharma Germany and sold in pharmacies.

Overall, the new draft laws on sustainability reporting are a step in the right direction for companies and society in general. However, the reaction of Pharma Germany and other interest groups shows that the complexity and burdens of bureaucracy continue to be a serious challenge. It remains to be seen how the implementation of the CSRD directive in Germany will actually look and what effects this will have on companies and society.

Date: Berlin